Quarterly Result6 Feb 2026, 02:01 am
Viyash Scientific Ltd: Q3 FY26 Revenues Up 10.9%, EBITDA* Surges 64.4%, PAT Increases 15.5%
AI Summary
Viyash Scientific Ltd, a leading integrated pharmaceutical company, announced its financial results for the quarter ended December 31, 2025. The results reflect the first quarter where the merged entity's results are being presented. The company reported a 10.9% increase in revenues and a significant 64.4% surge in EBITDA*. The net profit also increased by 15.5% in Q3 FY26. The company is poised for growth with a strong balance sheet and market position.
Key Highlights
- Revenues for Q3 FY26 at INR 8,584 Million, up by 10.9%
- EBITDA* for Q3 FY26 at INR 1,854 Million, up by 64.4%
- PAT for Q3 FY26 up by 15.5% including exceptional merger related costs
- Net Debt / EBITDA at 0.38 x
- Company to build Companion animal portfolio & CDMO services